This page shows the latest Heptares news and features for those working in and with pharma, biotech and healthcare.
products. Another deal – signed with Sosei Heptares this week – will see GSK collaborate on the discovery and development of a small molecule target for inflammatory bowel disease and other gastrointestinal immune
Targeting largest family of proteins in cell membranes. Sosei Heptares has enticed another big biopharma company to sign up to its G-protein coupled receptor (GPCR) drug discovery platform. ... Sosei Heptares has developed considerable expertise in GPCRs
The specific targets remain under wraps for now, although Sosei Heptares says they address metabolic and inflammatory diseases. ... The company was officially rebranded Sosei Heptares last December, but is still operating largely independently as a wholly
The drug is one of the lead candidate from a $3.35bn licensing deal Allergan agreed with Sosei’s Heptares Pharma subsidiary two years ago, covering global rights to a portfolio
biologics drugs - and will pay up to $189m per project to Heptares as well as an undisclosed upfront payment. ... Pfizer's agreement with Heptares is notable because it spans so many targets and indications, according to the UK firm's chief executive
Signs$410m alliance for early-stage candidates in potentially-lucrative drug class. Teva will co-develop Heptares Pharma's portfolio of migraine therapies in a new alliance valued at up to $410m. ... The agreement - which includes a $10m upfront payment
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
Whereas in the past the sector had “a very singular focus on amyloid”, Sosei Heptares’ chief R&D officer Malcolm Weir said he now thinks it is looking at targets “in ... Other groups, including Sosei Heptares, are working on novel ways to modify
Dr Fiona Marshall has joined MSD from Heptares Therapeutics, the UK biotech company she co-founded more than a decade ago, which was acquired by Sosei in 2015.
rights to Heptares’ G protein-coupled receptor product for pain relief. ... 20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.
Allergan must have known for some time that the Pfizer acquisition was likely to collapse because on the same day as the announcement, Allergan announced a $3.3bn deal with Heptares ... 9, 800. Heptares (JP). Allergan (IE). License and collaboration.
455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine. ... 225. Heptares. Pfizer. Strategic discovery collaboration. New therapeutics against up to 10 GPCR targets across
More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.
Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.
He has served as a non-executive director at Sosei since 2010, and has since worked at Syngene International, where he was chief executive and executive director, and Heptares Therapeutics, where
Also has experience at Merck &Co. Heptares has appointed Amgen's former executive VP, R&D, Dr Roger Perlmutter, to its board of directors. ... Dr Perlmutter said: “Heptares has pioneered structure determination in GPCRs, and has used this information
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...